{"filings":[{"id":499445,"accession_number":"0001104659-26-063202","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-05-18T20:15:33+00:00","items":["5.02"],"status":"ready","headline":"Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board","event_type":"leadership","confidence":"high","bullets":["Dr. Stefan Loren will not stand for reelection at 2026 annual meeting; no disagreement with the company.","Loren enters consulting agreement: $15,000/quarter for one year, plus 15,000 stock option grant.","Andrew Gu appointed as Class III director on May 18, 2026, selected by Nantahala Capital Management.","Gu is an analyst at Nantahala, focuses on biotech; he joins the Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77601,"accession_number":"0001104659-26-060693","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-05-14T11:20:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.","Positive 12-month follow-up from CLOVER WaM: 61.8% MRR, 83.6% ORR, median PFS 13.5 months in r/r WM.","Completed $35M upfront + up to $105M milestone financing led by Nantahala Capital; Andrew Gu to join board.","Initiated Phase 1b trial of CLR 125 in triple negative breast cancer; first patient dosed. Dosimetry data expected mid-2026.","Selected for ASCO 2026 presentation of CLOVER-WaM subgroup data on iopofosine post-BTKi therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91886,"accession_number":"0001104659-26-057460","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.","Phase 2b CLOVER WaM: 83.6% ORR, 61.8% MRR, median DoR 17.8 months in r/r WM.","BTKi-exposed: 64.1% MRR, median PFS 15.9 mo; BTKi-refractory: 63.6% MRR, median PFS 14.8 mo.","Nantahala gets board seat; warrants exercisable upon stockholder approval at $2.65.","Proceeds to support Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102286,"accession_number":"0001104659-26-023169","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026","event_type":"earnings","confidence":"high","bullets":["Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.","Cash $13.2M at Dec 31, 2025, expected to fund operations into Q3 2026.","Plans to submit Conditional Marketing Authorization for iopofosine I 131 to EMA in Q3 2026.","Initiated Phase 1b study of CLR 125 in triple negative breast cancer; early data mid-2026.","Received FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory WM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118577,"accession_number":"0001104659-25-110848","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.","Cash $12.6M at Sep 30, plus $5.8M from Oct warrant exercises; runway into Q3 2026.","EMA SAWP confirmed iopofosine I 131 may qualify for Conditional Marketing Approval in WM; submission planned 2026.","Phase 1b of CLR 125 (Auger-emitter) for triple-negative breast cancer initiated; RPDD granted for iopofosine in pediatric high-grade glioma.","Raised ~$12.7M in Q3; funds to advance TNBC study and EMA application."],"consensus_eps_estimate":-2.578,"consensus_eps_actual":-7.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118576,"accession_number":"0001104659-25-098725","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01","2.02","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Cellectar raises ~$5.8M via warrant exercise; prelim cash $12.6M as of Sep 30","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$5.8M from exercise of 1,048,094 existing warrants at $5.25/share; holders paid $0.125 per new warrant.","Preliminary cash and equivalents ~$12.6M as of Sep 30, 2025; combined with net proceeds of ~$5.2M, runway extends into Q3 2026.","Issued Series I warrants (exercisable at $6.00, 5-yr term) and Series II warrants (exercisable at $6.00, 18-mo term) for 100% of exercised shares.","Company to file a resale registration statement for new warrant shares within 15 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118575,"accession_number":"0001104659-25-096928","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"EMA confirms iopofosine I 131 eligible for Conditional Marketing Authorization in post-BTKi WM","event_type":"regulatory","confidence":"high","bullets":["SAWP advised filing a CMA for iopofosine I 131 in post-BTKi refractory WM could be acceptable.","CMA submission planned for early 2026; potential commercial launch in up to 30 EMA countries by 2027.","CLOVER WaM Phase 2 study showed ORR 83.6%, MRR 58.2%; >70% patients were post-BTKi.","Company also pursuing US NDA under accelerated approval, contingent on funding for confirmatory study.","Estimated 35,000-45,000 WM patients in Europe with significant unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135049,"accession_number":"0001104659-25-078102","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar to pursue accelerated NDA for iopofosine I 131 in WM; Q2 net loss $5.4M","event_type":"earnings","confidence":"high","bullets":["Plans NDA submission for accelerated approval of iopofosine I 131 in WM, subject to sufficient funding and confirmatory trial initiation.","FDA granted Breakthrough Therapy Designation for iopofosine I 131; EMA decision on conditional approval expected late Q3/early Q4 2025.","Raised ~$9.5M in June/July financings; cash $11.0M at June 30, 2025, plus July net proceeds funds operations into Q2 2026.","CLR 125 Phase 1 TNBC trial protocol submitted to FDA; plan to advance into clinic 4Q 2025/early 2026.","Q2 2025 net loss $5.4M ($3.39 per share); R&D $2.4M, G&A $3.6M; both down YoY."],"consensus_eps_estimate":-3.978,"consensus_eps_actual":-7.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152013,"accession_number":"0001104659-25-062837","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing","event_type":"other_material","confidence":"high","bullets":["CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.","CLR 225 (alpha-emitting, actinium-225) Phase 1 imaging and dose-escalation safety study in solid tumors planned for H2 2025, subject to financing.","CLOVER-WaM study of iopofosine I 131 in Waldenström macroglobulinemia met primary endpoint with MRR of 58.2% (p<0.0001), ORR 83.6%, and 7.3% CR rate.","No treatment-related deaths in CLOVER-WaM study; most common Grade 3+ TRAEs were thrombocytopenia (81.5%) and neutropenia (66.2%), all patients recovered.","Proposed securities offering to fund operating expenses and initiate CLR 125 and CLR 225 clinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152012,"accession_number":"0001104659-25-062639","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Cellectar Biosciences completes 1-for-30 reverse stock split effective June 24, 2025","event_type":"other","confidence":"high","bullets":["Reverse split ratio set at 1-for-30 for common stock, par value $0.00001.","Amendment to Second Amended and Restated Certificate of Incorporation filed.","Fractional shares not issued; aggregate fractions sold by transfer agent and net proceeds distributed pro rata."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152011,"accession_number":"0001104659-25-060661","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cellectar Biosciences announces 1-for-30 reverse stock split; effective June 24, 2025","event_type":"other_material","confidence":"high","bullets":["Approved by stockholders at June 13, 2025 annual meeting; board set final ratio as 1-for-30.","Reduces outstanding shares from ~54.4M to ~1.8M; effective at 12:01 a.m. ET on June 24.","Fractional shareholders will receive cash in lieu; authorized shares and par value unchanged.","Ticker remains CLRB on Nasdaq; new CUSIP number 15117F880 begins June 24.","Outstanding options, warrants, and preferred stock conversion ratios adjust proportionately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152010,"accession_number":"0001104659-25-059400","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cellectar shareholders approve reverse stock split, re-elect directors","event_type":"other_material","confidence":"high","bullets":["Elected James V. Caruso and Frederick W. Driscoll as Class II directors; Caruso 5,478,892 for, Driscoll 6,207,218 for.","Ratified Deloitte & Touche as independent auditor for FY2025 with 16,651,803 votes for, 219,578 against.","Approved reverse stock split of common stock at ratio 1:10 to 1:30, as determined by Board; 13,464,719 for.","Approved non-binding advisory vote on named executive officer compensation: 5,050,203 for, 2,230,519 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152009,"accession_number":"0001104659-25-056697","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["1.01","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Cellectar Biosciences raises $2.5M via warrant exercise inducement at $0.3041/share","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.5M from immediate exercise of 8,301,322 outstanding warrants at $0.3041/share.","Warrants originally issued on June 5, 2020, Oct 25, 2022, and July 21, 2024; no replacement warrants issued.","Closing expected on or about June 6, 2025; Ladenburg Thalmann acting as exclusive placement agent.","Net proceeds for general corporate purposes including working capital and operating expenses.","All shares underlying the warrants are registered or resale-registered with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}